China NMPA Drug Inspection - Henan Hongri Kangrentang Pharmaceutical Co., Ltd. - Danshen Formula Granules
China NMPA drug inspection for Henan Hongri Kangrentang Pharmaceutical Co., Ltd. published September 28, 2023. Drug: Danshen Formula Granules. The National Medical Products Administration (NMPA) of China, through Announcement No. 48 of 2023 on September 28, 2023,
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Henan Hongri Kangrentang Pharmaceutical Co., Ltd. published September 28, 2023. Drug: Danshen Formula Granules. The National Medical Products Administration (NMPA) of China, through Announcement No. 48 of 2023 on September 28, 2023,
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox